Johnson & Johnson Submits Application Seeking U.S. FDA Approval of Simponi for the Treatment of Pediatric Ulcerative Colitis
December 18, 2024
December 18, 2024
NEW BRUNSWICK, New Jersey, Dec. 18 (TNSres) -- Johnson and Johnson issued the following news release:
* * *
Submission aims to expand SIMPONI ulcerative colitis indication to include pediatric population
* * *
HORHSAM, Pa. (December 16, 2024) - Johnson & Johnson today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking expanded approval of SIMPONI (golimumab) . . .
* * *
Submission aims to expand SIMPONI ulcerative colitis indication to include pediatric population
* * *
HORHSAM, Pa. (December 16, 2024) - Johnson & Johnson today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking expanded approval of SIMPONI (golimumab) . . .